Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial
Sleep and recovery: Deeper, more restorative sleep becomes a reliable pattern rather than an occasional effect Post-exercise recovery improves less soreness, faster return to baseline Minor soft tissue aches (old nagging injuries) may begin to feel better Body composition (early signals): Skin quality begins to improve increased hydration and elasticity from GH-driven collagen synthesis Subtle reduction in subcutaneous water retention, particularly around the midsection Appetite patterns shift some users report increased hunger (GH is a counterregulatory hormone), others report better appetite regulation Energy and mood: More consistent energy levels through the day Improved sense of well-being GH influences neurotransmitter function and this often manifests as a subtle mood elevation DAC vs no-DAC difference: By week 2-4, DAC users on a 1-2x/week schedule have accumulated sustained IGF-1 elevation
Final coverage always depends on your plan type + your specific plan design
Mechanisms of Action of KPV and BPC-157 Peptide Combination KPV peptide is a vasoactive peptide that can dilate blood vessels, improve blood flow, and reduce blood pressure
